Expression of EZH2 in renal cell carcinoma as a novel prognostic marker

Pathology International

Volumn 62, Issue 11, 2012, Pages 735-741

  Lee, Hye Won ^a   Choe, Misun ^a  

^a Dongsan Medical Center   (South Korea)

Author keywords

Enhancer of zeste homolog 2; Immunohistochemistry; Kidney; Prognosis; Renal cell carcinoma

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; POLYCOMB REPRESSIVE COMPLEX 2; REPUBLIC OF KOREA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84868316043     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12001     Document Type: Article

References (33)

1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-57.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003; 30: 467-80.
4. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L. The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000; 8: 174-80.
5. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 2003; 112: 599-606.
6. Jung JW, Lee S, Seo MS etal. Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci 2010; 67: 1165-76.
7. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-9.
8. Raaphorst FM. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 2005; 14: Spec No 1: R93-R100.
9. Varambally S, Dhanasekaran SM, Zhou M etal. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
10. Kleer CG, Cao Q, Varambally S etal. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11.
11. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005; 75: 252-7.
12. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 2007; 34: 597-600.
13. Edge SB, ed. AJCC Cancer Staging Manual, 7th edn. New York: Springer-Verlag, 2009.
14. Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: Advancing paradigms. Oncology (Williston Park) 2012; 26: 290-301.
15. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v137-9.
16. Yu J, Cao Q, Mehra R etal. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-31.
17. Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
18. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106: 243-7.
19. Li H, Bitler BG, Vathipadiekal V etal. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) 2012; 5: 484-91.
20. Wagener N, Holland D, Bulkescher J etal. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545-50.
21. Wagener N, Macher-Goeppinger S, Pritsch M etal. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010; 10: 524.
22. Hinz S, Weikert S, Magheli A etal. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol 2009; 182: 2920-25.
23. Komohara Y, Harada M, Arima Y etal. Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol 2007; 177: 1157-62.
24. Said J. Biomarker discovery in urogenital cancer. Biomarkers 2005; 10 Suppl 1: S83-6.
25. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30: 2670-8.
26. Takawa M, Masuda K, Kunizaki M etal. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011; 102: 1298-305.
27. Smits M, Mir SE, Nilsson RJ etal. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011; 6: e16282.
28. Lu C, Han HD, Mangala LS etal. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-97.
29. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-35.
30. Dang X, Ma A, Yang L etal. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205: 113-23.
31. Varambally S, Cao Q, Mani RS etal. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-9.
32. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011; 32: 1607-14.
33. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: Time for clinical application? Crit Rev Oncol Hematol 2012; 83: 184-93.